151 related articles for article (PubMed ID: 16170172)
1. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
[TBL] [Abstract][Full Text] [Related]
6. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Zimmerman TM; Harlin H; Odenike OM; Berk S; Sprague E; Karrison T; Stock W; Larson RA; Ratain MJ; Gajewski TF
J Clin Oncol; 2004 Dec; 22(23):4816-22. PubMed ID: 15570084
[TBL] [Abstract][Full Text] [Related]
7. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
Chang SM; Kuhn J; Wen P; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; Cloughesy T; De Angelis L; Razier J; Hess K; Dancey J; Prados MD;
Invest New Drugs; 2004 Nov; 22(4):427-35. PubMed ID: 15292713
[TBL] [Abstract][Full Text] [Related]
8. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
[TBL] [Abstract][Full Text] [Related]
10. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.
Kuhn JG
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):33-40. PubMed ID: 12199631
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
Kuhn JG; Chang SM; Wen PY; Cloughesy TF; Greenberg H; Schiff D; Conrad C; Fink KL; Robins HI; Mehta M; DeAngelis L; Raizer J; Hess K; Lamborn KR; Dancey J; Prados MD;
Clin Cancer Res; 2007 Dec; 13(24):7401-6. PubMed ID: 18094423
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
Haas-Kogan DA; Banerjee A; Kocak M; Prados MD; Geyer JR; Fouladi M; McKnight T; Poussaint TY; Broniscer A; Blaney SM; Boyett JM; Kun LE
Neuro Oncol; 2008 Jun; 10(3):341-7. PubMed ID: 18417739
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Olivi A; Grossman SA; Tatter S; Barker F; Judy K; Olsen J; Bruce J; Hilt D; Fisher J; Piantadosi S;
J Clin Oncol; 2003 May; 21(9):1845-9. PubMed ID: 12721262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
